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The intestinal barrier, consisting of the vascular endothelium, epithelial cell lining, and
mucus layer, covers a surface of about 400 m2. The integrity of the gut wall is
sustained by transcellular proteins forming tight junctions between the epithelial cells.
Protected by three layers of mucin, the gut wall forms a non-permeable barrier,
keeping digestive enzymes and microorganisms within the luminal space, separate
from the blood stream. Microorganisms colonizing the gut may produce bacteriocins
in an attempt to outcompete pathogens. Production of bacteriocins in a harsh and
complex environment such as the gastro-intestinal tract (GIT) may be below minimal
inhibitory concentration (MIC) levels. At such low levels, the stability of bacteriocins may
be compromised. Despite this, most bacteria in the gut have the ability to produce
bacteriocins, distributed throughout the GIT. With most antimicrobial studies being
performed in vitro, we know little about the migration of bacteriocins across epithelial
barriers. The behavior of bacteriocins in the GIT is studied ex vivo, using models, flow
cells, or membranes resembling the gut wall. Furthermore, little is known about the
effect bacteriocins have on the immune system. It is generally believed that the peptides
will be destroyed by macrophages once they cross the gut wall. Studies done on the
survival of neurotherapeutic peptides and their crossing of the brain–blood barrier, along
with other studies on small peptides intravenously injected, may provide some answers.
In this review, the stability of bacteriocins in the GIT, their effect on gut epithelial cells,
and their ability to cross epithelial cells are discussed. These are important questions
to address in the light of recent papers advocating the use of bacteriocins as possible
alternatives to, or used in combination with, antibiotics.
Keywords: bacteriocins, antibiotics, microbiota, gut–blood barrier, probiotics
INTRODUCTION
Bacteriocins are ribosomally synthesized peptides with antibacterial activity (Cavera et al., 2015).
Post-translationally modified bacteriocins are grouped in class I and are divided into four
subclasses based on the type of modification, biological activity, and biochemical properties (Heng
et al., 2006; Alvarez-Sieiro et al., 2016). Membrane-active peptides with thioether-containing amino
acids lanthionine (Lan) and β-methyllanthionine (MeLan) are grouped in class I. According to
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the classification scheme proposed by Heng et al. (2006),
class I is subdivided into three types (types A–C). Linear
lantibiotics are classified as type A and subdivided as A1,
nisin-like, or AII, SA-FF22-like. Globular lantibiotics, such
as mersacidin and cinnamycin, are classified as type B.
Multi-component lantibiotics, requiring two or more modified
peptides for bioactivity, are classified as type C. Arnison et al.
(2013) extended the nomenclature of ribosomally synthesized
and post-translationally modified peptides and proposed that
lanthipeptides be divided into four classes based on their amino
acid sequence. The authors also suggested that unmodified, non-
lantibiotic, membrane active, heat-stable bacteriocins be grouped
in class II, with three subclasses based on structural differences
and their mode of action. Anti-Listeria, pediocin-like peptides,
are grouped into subclass IIa and bacteriocins that require two or
more peptides for activity in subclass IIb. Unmodified inhibitors
that are non-pediocin-like or multi-component bacteriocins are
groups into subclass IIc. Large heat liable bacteriocins are
grouped in class III, subdivided into IIIa (bacteriolysins) and
IIIb (non-lytic proteins), and cyclic bacteriocins are grouped in
class IV.
Most antimicrobial peptides are positively charged and smaller
than 10 kDa (with the exception of the class III bacteriocins).
Their small size, charge, and variation in hydrophobic and
hydrophilic properties allow them to adhere to microbial cells
and penetrate phospholipid membranes (Izadpanah and Gallo,
2005). Bacteriocins adhere to target organisms via “docking
molecules.” Lipid II, for example, serves as the docking
molecule for several lantibiotics (mostly nisin-like). Mannose
phosphotransferase proteins IIC/D serves as docking molecule
for class IIa bacteriocins (Diep et al., 2007). The mode of action
is either pore formation, thus destabilizing the proton motive
force, or inhibition of DNA-, RNA-, and protein-synthesis (Nishie
et al., 2012; Cotter et al., 2013). Some bacteriocins exhibit a
much broader spectrum of activity and may extend beyond the
borders of bacteria to include protozoa, yeast, fungi, viruses, and
eukaryotic cells (e.g., cancer cells and spermatozoa; Reddy et al.,
2004; Drider et al., 2016; Chikindas et al., 2017).
In their natural environment, bacteria produce bacteriocins
to compete against other bacteria for nutrients. Complex
environments with changes in growth conditions, nutrients, pH,
water activity (Aw), and temperatures will have an effect on
bacterial cell numbers, their metabolic activity, and bacteriocin
production. In the gastro-intestinal tract (GIT), changes in food
particles and fluctuation in spices, additives, salts, bile, digestive
enzymes, etc., may have a negative impact on cell growth and
bacteriocin production. Once secreted by the producer cells,
the activity of bacteriocins may be affected by their ability to
adhere to food particles and diffuse through the digesta, but
also their stability at different pH values, resistance to digestive
enzymes and proteolytic enzymes, and chemical interactions
with particles and microbial cells in the GIT. On the other
hand, an increase in salt or EDTA levels may increase the
sensitivity of Gram-negative bacteria to bacteriocins (Dykes and
Hastings, 1998; Bouttefroy and Milliere, 2000; Vignolo et al.,
2000). It is thus extremely difficult to visualize the functioning of
bacteriocins in the GIT. The production of nisin A, for example,
is regulated by a protein pheromone, via a two-component
signal transduction system similar to quorum-sensing systems.
In a fermentor, the addition of nisin to a culture stimulates the
expression of nisin. This may very well be the situation in the
GIT. An increase in bacteriocin levels, e.g., when adhered to
lipids in the mucus layer, may have an effect on the expression
of genes encoding bacteriocin production. These are intriguing
questions and need to be studied, as it may affect the levels at
which bacteriocins accumulate in the GIT. If concentrated in
localized areas of the GIT, bacteriocins may cross the epithelial
barrier easier.
A recent study, conducted by Drissi et al. (2015), explored
the role bacteriocins may have in the GIT. In a genome
mining project, the authors retrieved 641 genomes (307
whole genomes and 334 draft genomes) from microorganisms
in the human gut. The genomes represented 199 bacterial
genera, including Lactobacillus, Streptococcus, Clostridium, and
Bacillus. A bidirectional protein BLAST, compared to bacteriocin
sequences listed in the BUR database, revealed that 317 of
the genomes encoded putative bacteriocins of classes I (44%),
II (38.6%), and III (17.3%). This supports the hypothesis
that bacteriocins are widespread across the GIT. Of the 317
putative bacteriocins, 175 were from Firmicutes (which includes
LAB), 79 from Proteobacteria, 34 from Bacteroidetes, and 25
from Actinobacteria. The high number of bacteriocins being
(hypothetically) produced by Proteobacteria may explain why
they are so persistent and virulent. The study also suggested that
bacteriocins produced by gut bacteria are generally smaller in
size and differ in amino acid composition compared to most
other bacteriocins. Furthermore, these (putative) bacteriocins
contained less aspartic acid, leucine, arginine, and glutamic
acid, but more lysine and methionine. Based on their α-helical
structure, charge, and hydrophobicity, they possibly have a
broad spectrum of antimicrobial activity (Dathe and Wieprecht,
1999; Giangaspero et al., 2001; Zelezetsky and Tossi, 2006).
Considering these findings, the bacteriocins produced by gut
bacteria, especially Firmicutes and Proteobacteria, may render
them a competitive advantage over other bacteria in the GIT
(Schuijt et al., 2013). Drissi et al. (2015) speculated that
bacteriocins in the GIT may have low levels of antimicrobial
activity and may thus not have such a drastic effect on microbial
populations. This makes sense, as it supports the existence of
a large variation of gut bacteria, thus a balanced population. If
bacteriocins play a lesser role in population dynamics, they may
have a greater role to play in quorum sensing, or possibly in host
immune modulation.
FROM FOOD PRESERVATIVES TO
INFECTION FIGHTERS
A few decades ago most research groups studied bacteriocins
of LAB for their food preservation properties (Cotter et al.,
2005). Since most LAB have generally regarded as safe (GRAS)
status, their bacteriocins are regarded safe by the US Food
and Drug Administration (Chen and Hoover, 2003; Montville
and Chikindas, 2013). However, despite all the research on
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bacteriocins, only a few have been approved as food preservatives.
Of these, the lantibiotic nisin, produced by Lactococcus lactis
subsp. lactis, is the best studied and is used to preserve a number
of foods, mostly dairy products and canned vegetables (Johnson
et al., 2017). Bacteriocins produced by Pediococcus acidilactici
have also been added to fresh milk to prevent the growth of
Listeria spp. (Johnson et al., 2017). Several bacteriocinogenic
LAB have been used as starter cultures, e.g., the fermentation
of sausages and cheese (e.g., P. acidilactici and Lactobacillus
plantarum) and vacuum-packed beef, e.g., Leuconostoc gelidum
(Johnson et al., 2017).
During the last decade, an increasing number of papers
were published suggesting that bacteriocins may be used in
the prevention or treatment of bacterial infections (Table 1).
However, despite these evidences, only nisin has been approved
for use in oral/topical use. Other peptide antibiotics approved
for clinical use include gramicidin, daptomycin, vancomycin,
and polymyxin, which are non-ribosomally synthesized and
thus not classified as bacteriocins. The diversity of bacteriocin-
producing bacteria and the wealth of literature supporting the
efficacy of bacteriocins in vivo render them ideal candidates
for treatment of bacterial infections. The development of
bacteriocins for clinical applications is, however, hampered
by production costs, stability/solubility issues, and possible
cytotoxic effects. These shortcomings can be overcome.
Nisin and lacticin 3147, for instance, can be produced cost
effectively at large scale with optimization of fermentation
techniques and the use of heterologous expression systems.
Companies such as Novacta Biosystems and Oragenics are
developing large-scale fermentation and recovery processes for
lantibiotics. Another company spearheading the development of
lanthipeptides is LanthioPharma that focus on the discovery and
development of lanthipeptide-based drugs for various clinical
(other than antimicrobial) applications. By using lanthipeptides,
LanthioPharma are developing novel peptides, and incorporating
lanthionines into existing peptides (e.g., apelin), that are more
stable and resistant to protease degradation. Bacteriocins can also
be delivered via bacteriocin-producing bacteria. Two strains are
being commercialized for their ability to produce bacteriocins
(BLIS K12TM and BLIS M18TM). Many probiotic formulations
contain strains that produce bacteriocins; however, they are not
marketed as such. Probiotic bacteria may serve as a method of
delivering bacteriocins to the GIT, in that the cells protect the
peptides against acids and proteases in the stomach (Marteau
and Shanahan, 2003).
The mode of action of bacteriocins is remarkably different
from conventional antibiotics and the machinery used by
pathogens to develop resistance should be different. With this
in mind, bacteriocins may be considered as “new age infection
fighters.”
THE NEED FOR ALTERNATIVE
ANTIMICROBIALS
The discovery of penicillin in 1928 by Alexander Fleming
was a life-changing event in the history of medicine
(Tan and Tatsumura, 2015). However, the first report of
pathogenic Staphylococcus aureus strains resistant to penicillin
was published in the early 1940s (Chambers and Deleo, 2009).
This urged scientists to search for alternative antibiotics and
sulfonamides that were described in 1935. More than 20 classes of
antibiotics were described between 1940 and 1962 (Coates et al.,
2002; Powers, 2004), referred to as the “golden age” of antibiotics.
Looking back, it seems as if everyone was at peace with the
antibiotics on the market. No new classes of antibiotics were
developed between 1968 and 1998. In fact, the few antibiotics
developed up to 1960 had to suffice in curing all types of bacterial
infections for the next 50 years (Coates et al., 2011). In hindsight,
this was an unreasonable expectation, keeping in mind the rate at
which antibiotics develop resistance (Bax et al., 1998). Infections
caused by Gram-negative bacteria are becoming increasingly
difficult to treat, as many strains produce metallo-β-lactamase
that neutralize carbapenems (Kumarasamy et al., 2010). With
the current rate at which bacteria develop resistance, we may
need more than 20 new classes of antibiotics to last the next 50
years, i.e., treat infections up to 2060. Nowadays, most of the
deaths caused by S. aureus are due to methicillin-resistant strains
(MRSA; Klein et al., 2007).
Clostridium difficile may be added to the list of most feared
pathogens, the so-called ESKAPE group (Enterococcus faecium,
S. aureus, Klebsiella pneumoniae, Acinetobacter baumanii,
Pseudomonas aeruginosa, and Enterobacter species). Infections
caused by C. difficile increased dramatically over the last
decade, especially in patients with irritable bowel disease (IBD;
Nguyen et al., 2008). Severe cases of CDI are treated with oral
metronidazole (250–500 mg four times a day for 10–14 days), or
oral vancomycin (125–500 mg four times a day for 10–14 days).
Metronidazole is often administered intravenously, in doses of
500 mg four times daily (Persky and Brandt, 2000). Although
metronidazole is the antibiotic of choice, failure rates of 22–38%
have been reported and many strains have developed resistance
(Miller et al., 2010, 2011).
The alarming rate at which strains become resistant is
understandable, considering that antibiotics are among the most
commonly prescribed drugs (Centers for Disease Control and
Prevention [CDC], 2013). As many as 50% of the prescribed
antibiotics are either not required, or are not effective in
treating the infection. Despite this, doctors continue to prescribe
antibiotics. In the United States, more than five prescriptions
are written each year for every six patients (Truter, 2015).
This leads to the natural selection of bacteria resistant to
not one, but several antibiotics (Thomsen, 2016). Genes
encoding resistance to antibiotics is shared among pathogens,
often across species borders, through horizontal gene transfer.
The World Health Organization (WHO) has already declared
antibiotic resistance a global crisis, worse than the AIDS
epidemic. Antimicrobial resistance to tuberculosis, hospital
acquired infections, and common bacterial diseases is increasing
mortality rates drastically. At least two million individuals in
the United States contract serious antibiotic-resistant bacterial
infections each year (O’Neill, 2014). Approximately 23,000
people die each year due to infections caused by antibiotic-
resistant bacteria.
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TABLE 1 | Examples of bacteriocins with bioactivity and their potential applications.
Bacteriocin Producer strain Tested Bioactivity Potential Applications References
Nisin Lactococcus lactis In vitro
In vivo
TC#
Antimicrobial agent
Anticancer agent
Immune modulation
Skin infections, GIT
infections, respiratory tract
infections, immune
modulation, gingivitis,
prosthetic implant
infections, cancer
treatment, wound healing
Howell et al., 1993; Aranha et al.,
2004; Bartoloni et al., 2004; De
Kwaadsteniet et al., 2009; Begde
et al., 2011; Van Staden et al.,
2011, 2012, 2015; Joo et al., 2012;
Campion et al., 2013; Heunis et al.,
2013; Kindrachuk et al., 2013;
Kamarajan et al., 2015; Van
Staden, 2015
Gallidermin/
epidermin
S. gallinarum/
S. epidermidis
In vitro
TC#
Antimicrobial agent Skin infections, prosthetic
implant infections
Bonelli et al., 2006; Kindrachuk
et al., 2013; Bengtsson et al., 2018
Mersacidin Bacillus amyloliquefaciens In vitro
In vivo
TC#
Antimicrobial agent Skin infections Chatterjee et al., 1992; Kruszewska
et al., 2004
Duramycin Streptomyces
cinnamoneus
In vitro
In vivo
Antimicrobial agent
Immune modulation
Ion channel
modulation
Atherosclerosis treatment,
cystic fibrosis treatment,
immune modulation
Märki et al., 1991; Iwamoto et al.,
2007; Oliynyk et al., 2010; Zhao,
2011; Audi et al., 2012; Hasim
et al., 2018
Lacticin 3147 Lactococcus lactis In vitro
In vivo
Antimicrobial agent Skin infections, GIT
infections, mycobacterial
infections
Gardiner et al., 2007; Rea et al.,
2007; Piper et al., 2009, 2012;
Carroll et al., 2010
Peptide ST4SA Enterococcus mundtii In vitro
In vivo
TC#
Antimicrobial agent GIT infections Knoetze et al., 2008; Dreyer, 2018;
Van Zyl, 2018
Plantaricin 423 Lactobacillus plantarum In vitro
In vivo
TC#
Antimicrobial agent GIT infections van Reenen et al., 1998; Dreyer,
2018; Van Zyl, 2018
Piscicolin 126 Carnobacterium piscicola In vitro
In vivo
Antimicrobial agent GIT infections Jack et al., 1996; Ingham et al.,
2003
Pediocin PA-1 Pediococcus acidilactici In vitro
In vivo
Antimicrobial agent GIT infections Cintas et al., 1998; Dabour et al.,
2009
Divercin V41 Carnobacterium divergens In vitro
In vivo
Antimicrobial agent GIT infections Rihakova et al., 2009, 2010
Bac Abp118 Lactobacillus salivarius In vitro
In vivo
Antimicrobial agent GIT infections Flynn et al., 2002; Corr et al., 2007;
Riboulet-Bisson et al., 2012
Plantaricin A Lactobacillus plantarum In vitro
TC#
Antimicrobial agent
Anticancer agent Cell
migration/proliferation
Immune modulation
Cancer treatment, immune
modulation, wound healing
Hauge et al., 1998; Sand et al.,
2010, 2013; Pinto et al., 2011;
Marzani et al., 2012
#Tissue culture.
The peptide antibiotic vancomycin remains one of the most
successful in the treatment of infections caused by Gram-positive
bacteria. The reason is that vancomycin resistance would require
changes in multiple steps in the peptidoglycan pathway. Similar
to vancomycin, lanthipeptides such as nisin also targets a cell
wall component, in this case lipid II. The antibacterial activity of
antibiotics may be increased by combined use with a combination
of bacteriocins (Bastos et al., 2015; Cavera et al., 2015). The
most effective would be bacteriocins with different modes of
action, preferably from different classes, to rule out the possibility
of strains developing cross resistance (resistance to more than
one bacteriocin). Further research is required to bioengineer
bacteriocins with unique target sites and different modes of
activity.
Similar to antibiotics, strains treated with bacteriocins
may develop resistance (Arthur et al., 2014; Bastos et al.,
2015). Mechanisms involved in bacteriocin resistance are either
acquired or innate (Collins et al., 2012; Bastos et al., 2015).
Innate resistance may develop by mimicking the bacteriocin-
producing strain’s immunity system, degrading the bacteriocin,
or adapting to changes in the bacterial cell-envelope and growth
conditions (Bastos et al., 2015). Immunity mimicking is caused by
non-bacteriocin-producing strains with genes homologous to the
immunity genes of bacteriocin-producing strains. Expression of
the homologous genes confers protection against the bacteriocin.
Certain bacteria produce enzymes that degrade bacteriocins,
e.g., nisinase produced by Bacillus cereus and Paenibacillus
polymyxa (Jarvis, 1967). Mutations in genes coding for proteins
involved cell wall structure lead to changes in cell surface charge,
preventing the bacteriocin from binding to the cell. Stationary
phase cells of Listeria monocytogenes 412 were more resistant
to nisin and pediocin than cells in their exponential phase
(Jydegaard et al., 2000). This is attributed to the fact that cells
in stationary phase are more adaptable to stress conditions such
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as high or low osmotic concentrations, acidic conditions, and
heat shock (Hu and Coates, 2012). Unlike innate resistance, the
properties associated with acquired resistance are only found in
certain strains of a species (Bastos et al., 2015). The mechanisms
responsible for resistance vary greatly among strains and species.
Acquired resistance results from gene mutations or horizontal
gene transfer via transformation, conjugation, or transduction
(Collins et al., 2012), altering the cell wall, cell membrane,
receptors, and transport systems.
It is evident that we need novel antimicrobial compounds
to treat bacterial infections. Oxazolidinone (linezolid by Pfizer)
and cyclic lipopeptide (daptomycin by Cubist), with activity
against Gram-positive bacteria, including MRSA, are two of the
most recent antibiotics released into the market (Coates et al.,
2011). There may be a number of yet to be published antibiotics
that are currently in preclinical development, but the overall
conclusion is that we are heading for a disaster if antibiotics with
broader antimicrobial activity are not developed in the next few
years. The rate at which novel antibiotics are being developed
is just not sufficient to control bacterial infections. We need to
focus our efforts in developing antibiotics that target complex
bacterial systems, such as cell membranes. Bacteriocins may be
an alternative to antibiotics.
STRUCTURE OF THE GUT-BLOOD
BARRIER
The GBB is an intricate system, consisting of multiple layers
(Figure 1). It plays an important role in maintaining homeostasis
between the blood stream and GIT, and regulates the absorption
of water, electrolytes, and nutrients from the gut lumen (Kelly
et al., 2015). The intestinal barrier also serves as a protective
barrier by preventing pathogenic microorganisms and luminal
toxins from entering the blood stream (Farhadi et al., 2003). The
mucus layer (consisting of large, highly glycosylated proteins),
covering the epithelium, protects villi from physical friction
caused by luminal content, and contact with toxins and
bacteria (Farhadi et al., 2003). It forms an important diffusion
barrier, restricting the movement of molecules and pathogens.
Disruption of the intestinal mucus layer, or suppression of mucus
production, may lead to hyper permeability.
The epithelial layer is a single layer of epithelial cells that line
the gut lumen and are connected by desmosomes, tight junctions
(TJs) and adherens junctions (AJs). TJs and AJs use transcellular
proteins to connect to the actin cytoskeleton. The cytoskeleton is
crucial for paracellular transport. The TJs are distributed across
the gastro-intestinal membrane and the number of proteins
varies between the small intestine, large intestine, villi, and
crypts. The TJs control water and ion permeability, and the
absorption of proteins and bacterial antigens. Intestinal epithelial
cells (IECs) play an important role in the absorption of nutrients.
The epithelium mediates selective permeability by transcellular
and paracellular pathways. Lipophilic and small hydrophilic
molecules pass through the barrier transcellularly, while larger
hydrophilic molecules pass the barrier paracellularly. During
transcellular permeability, solutes are transported through the
epithelial cells. This is regulated by selective transporters for
amino acids, short chain fatty acids, electrolytes, and sugars.
During paracellular permeability, solutes are transported in
spaces between epithelial cells. This is regulated by intercellular
complexes present at the apical–lateral membrane junction.
Amino acids and vitamins are transferred by means of active
transport.
Nutrients, bacteria, and molecules that transverse the IEC
to gain access to the blood stream first need to cross the
vascular endothelium. Endothelial cells (ECs) line the interior
surface of blood vessels and lymphatic vessels and form the
endothelium (Michiels, 2003). ECs that make up the endothelium
are connected to each other by TJs, AJs, and gap junctions.
The endothelium is extremely important as it forms a selective
barrier for the movement of molecules between blood and
tissue. The existence of an additional barrier known as the
gut–vascular barrier (GVB) that restricts the size and type of
molecules translocating across the ECs has also been proposed
(Spadoni et al., 2015). To evaluate the presence of this barrier,
mice were injected with different molecular sizes of fluorescein
isothiocyanate (FITC)-dextran and examined the intestine for
any dye leakage. A molecule of 4 kDa had the ability to move
through the endothelial barrier, whereas a molecule of 70 kDa
could not. However, infection with Salmonella typhimurium
could disrupt the GVB, resulting in translocation of the 70 kDa
FITC-dextran (Spadoni et al., 2015).
Disruption of the epithelial and/or endothelial (GVB
included) layers results in permeability of these selective barriers,
which in-turn can lead to dysbiosis and subsequent disease states
(e.g., irritable bowel syndrome and celiac disease). It is therefore
crucial to maintain the integrity of the intestinal barrier, which
prevents the crossing of microbes through the gut–blood barrier
(GBB). However, the large body of literature in support of a gut
microbiota–host interaction suggests that even in the absence of
pathological increases in permeability of the barrier, some degree
of permeability exist that allows for GBB crossing of microbial
secretory products and/or metabolites – of which bacteriocins
may form part. Before reviewing the relevant evidence specific to
bacteriocins, it is relevant to consider how microbiota in general
interacts with the GBB. In this context, there are two main topics
to consider: first, how the microbiota enhances GBB integrity
and second, how microbiota achieves signaling to modulate host
health from within the gut as well as across the GBB.
THE EFFECT OF GUT MICROBIOTA ON
GBB INTEGRITY
Over the past few years, the importance of gut microbiota in
health and disease has caught significant attention. The manner
in which microbiota interacts with the GBB and affect its
permeability may have far reaching effects and may even lead
to dysbiosis. To minimize the risk of disease, it is important
to maintain a healthy gut microbiota. Furthermore, infections
targeting the GIT can cause dysbiosis in the microbiota which
is further exacerbated by the use of antibiotics. Additionally,
inflammation of the GIT can also result in dysbiosis of
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FIGURE 1 | The GBB consists of a mucus layer, a monolayer of epithelial cells, and a monolayer of endothelial cells that line blood vessels. This barrier protects the
host by preventing passage of harmful compounds or pathogens from the gut lumen to the bloodstream. Transcellular and paracellular transport and junctional
complexes and desmosomes are indicated. Figure created in biorender (http://biorender.io).
this complex system (Buttó and Haller, 2016). Maintaining
homeostasis within the GIT is of utmost importance as
disturbances in the natural microbiota and intestinal barrier
has been associated with several diseases such as such as IBD,
diabetes, Alzheimer’s and stress related behaviors (Foster and
McVey Neufeld, 2013; Simrén et al., 2013, Konstantinov et al.,
2008; Jiang et al., 2017; Li et al., 2017).
Several examples of probiotic bacteria modulating the
immune system and improving the GBB have been reported.
Probiotic strains of Bifidobacterium, Lactobacillus, and
Streptococcus used in a post-infectious IBD model, suppressed
the expression of pro-inflammatory cytokines IL-6 and IL-
17, and stimulated the expression of TJ proteins (claudin-1
and occluding), leading to enhanced barrier stability (Wang
and Kasper, 2014). Lactobacillus rhamnosus GG decreased
inflammation in an IL-10 receptor-dependent manner in an
immature murine colon (Mirpuri et al., 2012). The increase
in expression of the IL-10 receptor was also associated
with reductions in TNF-α and MIP-2, both of which are
pro-inflammatory. Bifidobacterium decreased production of
IL-6 and TNFα in Caco-2 monolayers stimulated with LPS.
Bifidobacterium also suppressed the expression of zonulin,
responsible for dismantling TJs. This modulated the permeability
of epithelium cells in Caco-2 monolayers, while upregulating the
expression of occluding, claudin-2 and ZO-1 (Ling et al., 2016).
The stabilizing effect Bifidobacterium has on Caco-2 monolayers
can be translated to the in vivo environment of the gut (Ling
et al., 2016). Probiotic Streptococcus and Lactobacillus strains
reversed the negative effects observed with epithelial cell lines
caused by entero-invasive Escherichia coli (Resta-Lenert and
Barrett, 2003). Probiotic strains of Lactobacillus acidophilus and
Streptococcus thermophilus increased trans-epithelial resistance
with pre-treated monolayers and protected the cells from
damage caused by E. coli. Probiotic administration was also
associated with phosphorylation of cytoskeletal (actin and
actinin) and TJ proteins (ZO-1 and occludin), providing stability
to TJs. Furthermore, Lactobacillus species are also capable of
stabilizing AJs through the increased expression of E-cadherin,
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as well as strengthening the E-cadherin/β-catenin complex
through enhanced phosphorylation of β-catenin (Hummel et al.,
2012). These studies and others illustrated how probiotics can
modulate the host immune system and reduce inflammation.
Enhancement of AJs and TJs maintains the intestinal barrier,
providing protection against damage and preserving the integrity
of the GBB.
Extracellular proteins secreted by Bifidobacterium breve C50
interacted with TLR-2 on the surface of immature DCs and
induced a number of functional and physiological changes.
Some of the effects included prolonged survival of DCs,
earlier maturation of DCs, and an increase in IL-10 and
IL-12 production (Hoarau et al., 2008). Proteins secreted
by probiotic lactobacilli are involved in maintenance of the
mucosal barrier, mainly through MAPK-dependent mechanisms
(Schlee et al., 2008). Proteinaceous compounds secreted by
L. acidophilus PZ 1138, Lactobacillus fermentum PZ 1162,
and Lactobacillus paracasei subsp. paracasei LMG P-17806
stimulated the production of b-defensin 2 (hBD2) in human
epithelial cells. The signal of these proteins was transduced
to the nucleus through the MAPKs ERK, p38, and c-Jun
terminal kinase (JNK). Synthesis of hBD2 increased through
modulation of nuclear factor kB (NF-kB) and the activator
protein 1 (AP-1). This resulted in increased IL-8 production
(Schlee et al., 2008). Two from L. rhamnosus GG (NPSRQERR
and PDENK) were antimicrobial toward E. coli EAEC 042,
Salmonella enterica serovar Typhimurium and S. aureus (Lu et al.,
2009).
Probiotic strains of Bifidobacterium, Lactobacillus, and
Streptococcus suppressed the expression of pro-inflammatory
cytokines IL-6 and IL-7, and stimulated the expression of TJ
proteins, leading to enhanced barrier stability. L. rhamnosus GG
interacted with intestinal cells and maintained the integrity of the
GBB (Bajaj et al., 2015). Several Lactobacillus spp. induce gene-
regulation pathways that lead to upregulation of IL-1β, resulting
in the transcription of genes involved in B-cell maturation
and lymphogenesis, which contributes toward enhanced barrier
stability and function. L. plantarum regulated human epithelial
TJ proteins in vivo and conferred protective effects against
chemically induced disruption of the epithelial barrier in an
in vitro model (Karczewski et al., 2010). Administration of
L. plantarum into the duodenum of healthy human volunteers
significantly increased ZO-1 and occludin in the vicinity of TJ
structures (Karczewski et al., 2010). These results suggest that
administration of L. plantarum can enhance the stability of TJ
complexes in humans and may attenuate their disruption by
cytokines, toxins, and pathogens.
The serine protease inhibitor (serpin) produced by
Bifidobacterium longum subsp. longum NCC2705 interact
directly with the host factors (Ivanov et al., 2006). Extracellular
serpin is also produced by other bifidobacterial species, including
B. breve, Bifidobacterium dentium, and B. longum subsp. infantis.
Serpin inhibits pancreatic and neutrophil elastases (Ivanov et al.,
2006). Neutrophils are recruited in the intestinal mucosa from
the blood vessels by means of the secretion of inflammatory
cytokines. Serpin produced by bifidobacterian act on enzymes
directly involved in the inflammatory response and might thus
mediate some of the anti-inflammatory effects reported for
bifidobacteria (Ivanov et al., 2006).
Proteinaceous compounds secreted by probiotic strains of
L. plantarum, L. acidophilus, Lactobacillus casei, and Lactobacillus
delbrueckii subsp. bulgaricus stimulated the expression of
the muc2 gene and increased the production of mucin by
murine colonic epithelial cells (Caballero-Franco et al., 2007).
Extracellular proteins produced by L. rhamnosus GG increased
production of the heat-shock proteins HSP25 and HSP72 in
murine colon cells (Tao et al., 2006). Protein p40, produced by
L. rhamnosus GG, is homologous to an uncharacterized surface
antigen of L. casei ATCC 334 (gi| 116493594) and protein p75 to a
cell wall-associated hydrolase of strain ATCC 334 (gi| 116493849;
Yan et al., 2007). Both these proteins induced the proliferation
of murine colonic epithelial cells and reduced injuries to colonic
cells caused by tumor necrosis factor alpha (TNF-a; Yan et al.,
2007). Proteins p40 and p75 inhibited TNF-a-induced apoptosis
in the KSRI2/2 MCE cell line (Yan et al., 2007) and attenuated the
TER decrease induced by hydrogen peroxide. Concluded from
these results, proteins p40 and p75 play an important role in cell
proliferation, apoptosis, and maintenance of the mucosal barrier.
EVIDENCE IN SUPPORT OF
BACTERIOCINS CROSSING THE GBB
Little is known about the cellular receptors responsible for
the recognition of extracellular proteins (thus also bacteriocins)
secreted by gut microbiota (Asong et al., 2009). Bacterial flagellins
are recognized by Toll-like receptor 5 (TLR-5) and by the
ICE protease-activating factor (IPAF; Gewirtz, 2006; Ren et al.,
2006). A particular TLR may recognize more than one type of
molecule, as in the case of TLR-2 recognizing different glycolipids
and lipoproteins (Yan et al., 2007). The C-type lectin receptor
(CLR) DC-specific ICAM-3-grabbing non-integrin (DC-SIGN)
may be involved in the recognition of extracellular components
produced by probiotic bacteria (Konstantinov et al., 2008). The
CLRs on the surface of immune cells, such as dendritic cells (DCs)
and macrophages, recognize carbohydrate patterns and thus also
glycoproteins (Benz and Schmidt, 2002). Glycolipids produced by
lactobacilli are recognized by intestinal receptors (Iwamori et al.,
2009).
Bacteriocin gene clusters are widespread in the genomes of
intestinal bacteria (Drissi et al., 2015). Several studies have shown
that bacteriocins are produced in the GIT and protect the host
against infection (Bron et al., 2004; Corr et al., 2007; Van Zyl,
2018). It is likely that bacteriocins interact with epithelial cells
in the GIT and even cross the GBB. Support for this comes
from studies conducted by Spadoni et al. (2015). The authors
showed that molecules of 4 kDa can cross the GVB. Most
bacteriocins are smaller than 7 kDa, suggesting that they are
small enough to cross the GVB. Other properties, such as charge,
hydrophobicity, and affinity to IECs and ECs also have to be taken
into account. A recent study has shown that bacteriocins can
indeed transverse epithelial (Caco-2) and endothelial (HUVECs)
monolayers (Dreyer, 2018). Nisin A (3.35 kDa), plantaricin
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423 (3.93 kDa), and bacST4SA (4.29 kDa), labeled with NHS-
fluorescein, crossed the epithelial and ECs without changing the
integrity of the monolayers or having a toxin effect (Dreyer,
2018). Although the exact mechanism for crossing IECs and
ECs was not examined, this study (albeit in vitro) provides
evidence that bacteriocins can cross the GBB. Crossing of these
peptides without eliciting a cytotoxic reaction suggests that they
were transported paracellular. However, migration of cationic
peptides via transcytosis (i.e., transcellular) cannot be ruled
out and it may be the way larger bacteriocins cross the GBB.
Transcytosis has been demonstrated for cell-penetrating peptides
and bacterial toxins (e.g., botulinum toxin and cholera toxin).
While bacteriocins have not been shown to cross the GBB
they have been used in studies where intravenous injections
resulted in treatment of intraperitoneal/subcutaneous infections
(Goldstein et al., 1998; Castiglione et al., 2007; Jabés et al., 2011).
Although this is different from the GBB, it supports the idea that
bacteriocins are capable of crossing endothelial barriers.
Irrespective of the method bacteriocins may transverse
the GBB, other challenges must also be overcome. Intestinal
conditions are not favorable for long-term bacteriocin survival,
with proteases and the mucus layer being the two most significant
barriers. The mucus layer is capable of binding peptides; however,
continuous production of bacteriocins may result in saturation,
with some of the peptides reaching the GBB. Another possibility
is bacteriocin production near the GBB, minimizing contact with
the mucus layer. Proteases can also degrade bacteriocins before
they reach the GBB. This may also be overcome by continuous
production of bacteriocins by cells colonized close to the GBB.
Of all sections in the GIT, bacteriocins are more likely to survive
conditions in the colon where protease levels are lower.
Based on the few studies thus far reported, bacteriocins
(maybe only a select few) do have the ability to cross the GBB.
However, more research is required to determine when and how
bacteriocins cross epithelial cells. Research should focus on the
mechanisms bacteriocins use to migrate over IECs and ECs and
whether specific receptors are involved. Furthermore, this should
be translated into the complex in vivo environment of the GIT,
keeping in mind that gut epithelial cells is not the only barrier.
Once in the blood stream, bacteriocins may cross the blood-brain
barrier. Little is known about the effect bacteriocins have once
they cross these barriers.
POTENTIAL EFFECTS OF
BACTERIOCINS ACROSS THE GBB
Although bacteriocins are generally non-toxic and considered
safe, exceptions do exist, e.g., cytolysin produced by enterococci,
which has wide-spread cytotoxic activity (Cox et al., 2005).
In most cases, cytotoxicity has only been noted at levels
much higher than the minimal inhibitory concentration (MIC)
required to inhibit food spoiling microorganisms (Lohans and
Vederas, 2012). A crude extract of antimicrobial peptides isolated
from L. plantarum LR/14 delayed the life cycle of Drosophila
melanogaster when administered at 10 mg/mL (Gupta et al.,
2014). The antimicrobial peptide P40, produced by Bacillus
licheniformis P40, was cytotoxic to VERO cells when tested
in vitro (Vaucher et al., 2010). A few bacteriocins displayed
activity against sperm and tumor cells (Reddy et al., 2004).
This is not that surprising, as bacteriocins may adhere to other
negatively charged molecules or non-bacterial lipophilic surfaces.
In a physiological environment this may cause a decrease
in bio-availability. Bacteriocins can bind to blood cells and
plasma proteins (Van Heel et al., 2011; Dreyer, 2018). Size and
biochemical properties of peptides administered orally may also
influence uptake and stability in the GIT (Cavera et al., 2015).
Bacteriocins are membrane active cationic peptides, and
may thus also have an effect on mammalian cell membranes.
Cinnamycin and duramycin bind phosphatidylethanolamine
(PE), a substrate for phospholipase A2 and involved in
inflammatory responses (e.g., vascular inflammation). The
sequestering of PE by cinnamycin and duramycin may thus
result in immune modulation through the indirect inactivation
of phospholipase A2. Furthermore, by binding PE, the peptides
may be deposited in cellular membranes, thereby potentially
changing biophysical membrane properties. These changes can
lead to altered ion channel functioning. In the case of duramycin,
this characteristic is exploited for the potential treatment of
cystic fibrosis. Minimal cytotoxic effects of bacteriocins against
human cell lines have been reported (Murinda et al., 2003;
Sand et al., 2010; Begde et al., 2011; Kindrachuk et al., 2013;
Dreyer, 2018). Given the concentration of bacteriocin required
to induce significant cytotoxicity, these levels would most likely
not be present as a result of bacteriocins crossing the GBB.
This, however, does not discount the possibility of bacteriocins
accumulating in organs such as the liver and causing membrane
damage.
If permeability is severely changed, gut microbiota may enter
the blood stream and cause bacteremia. Certain pathogens can
disrupt intracellular junctions by interacting with cell receptors.
Enteric pathogens often gain access to the body by altering the
structure and function of TJs to increase permeability of the
barrier via the secretion of proteases, which can cleave TJ proteins
or by altering the cytoskeleton (Berkes et al., 2003). Inflammatory
cytokines such as TNFα and IFNγ, which are induced during
infection and in IBD, increase intestinal permeability in general,
although single inflammatory models yielded different results
(Corridoni et al., 2012). Probiotics and commensal microbiota
can reverse such inflammatory dysfunctions in human IECs.
This is done by improving barrier functions or by inhibition of
pathogen adherence (Resta-Lenert and Barrett, 2006; Moorthy
et al., 2009; Qin et al., 2009; Anderson et al., 2010). Synergistic
effects between sIgA and probiotics have been published (Mathias
et al., 2010).
The lantibiotics gallidermin, Pep5, and nisin induce the release
of multiple chemokines at levels similar to that of the human
cationic antimicrobial peptide LL-37, with nisin seemingly able
to activate multiple signaling pathways, including ERK/MAPK,
PKC, and PKA (Kindrachuk et al., 2013). Nisin administered
prophylactically to mice confers protection to mice challenged
with Gram-positive (S. aureus) and Gram-negative (S. enterica
and E. coli) bacteria. This is significant keeping in mind that
nisin is ineffective against Gram-negative bacteria, suggesting
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FIGURE 2 | Possible effects of bacteriocins when crossing the GBB. Figure created in biorender (http://biorender.io).
that nisins’ interaction with the host’s immune response provides
a selective advantage. At high concentrations, nisin activates
neutrophils, resulting in formation of neutrophil extracellular
traps (Begde et al., 2011). Neutrophil extracellular traps are
known for trapping and killing bacteria (Zawrotniak and Rapala-
Kozik, 2013). Furthermore, loci harboring genes involved in
bacteriocin production and secretion modulate the immune
response of dendritic and peripheral blood mononuclear cells
(Meijerink et al., 2010; van Hemert et al., 2010). By enhancing the
hosts’ immune system, bacteriocins indirectly provide protection
against infectious microbial agents. These effects are not that
surprising as host cationic defense peptides also have immune
modulatory effects.
Several studies have shown that some bacteriocins have
anticancer properties (Kaur and Kaur, 2015). Bacteriocins
have a higher affinity for cancer cells due to the general
negative charge of cancer cells. Treatment of head and neck
squamous cell carcinoma (HNSCC) cells with nisin induced
DNA fragmentation and apoptosis on three different cancer cell
lines (Joo et al., 2012; Kamarajan et al., 2015). Apoptosis in
NHSCC cells, caused by nisin, is associated with calcium influx
and upregulation of CHAC1 (cation transport regulator and
apoptosis mediator; Joo et al., 2012). In another study, the size
of tumors in mice with oral cancer was reduced when treated
with nisin (Joo et al., 2012). The authors concluded that the
selective action of nisin was due to structural differences in
the composition of the plasma membranes between HNSCC
cells and primary keratinocytes. The class IIc human defensins-
like bacteriocin, laterosporulin 10, displays cytotoxic effects
against several cell lines and causes necrotic and apoptotic cell
death at high and low concentrations, respectively. At high
concentrations (10 µM), more than 95% of normal prostate
epithelial cells remained viable, whereas 80% of cancer cells
lost their viability. As with cytotoxicity against normal cells, the
concentrations used to be effective against cancerous cells may
be higher than the levels crossing the GBB. However, the higher
affinity for cancerous cells may result in bacteriocins targeting
these cells. Immune priming by bacteriocins may also assist in
the elimination of cancer cells. The possibility of bacteriocins
crossing the GBB is intriguing and from the literature, it is
clear that they are capable of effecting the host if they do cross
(Figure 2). However, if they do cross and if they exert an effect
requires further investigation.
CONCLUSION
The abundance and diversity of bacteriocins make them ideal
candidates for use in the treatment and prevention of infections.
In addition to high natural diversity, the bio-engineering
of bacteriocins and improvements in production processes
allow us to tailor bacteriocins so that they fit specific needs.
Non-antimicrobial properties of bacteriocins, such as immune
modulation, also introduce new applications. The most pertinent
question to answer is to what extent these bacteriocins are able
to cross the GBB to achieve these beneficial effects systemically.
Approval by medical control councils for using a newly developed
drug is a slow and tedious process and involves a number of
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safety tests and clinical trials. Natural antimicrobial peptides
and bacteriocins adhere to the same rules and regulations. To
establish the safety of bacteriocins, a number of tests will have
to be conducted. These include cytotoxicity studies incorporating
eukaryotic cell lines, the ability to induce apoptosis, inhibit
cellular growth, alter metabolic functions, and lyze red blood cells
(hemolytic activity). Further tests may include the development
of resistance to antimicrobial activity at therapeutic levels, effect
on the host’s immune system, and the development of allergies.
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